Meghana Keshavan

San Diego

Biotech Writer at STAT

Co-Writer at The Readout Newsletter

biotech nerd, biotech writer @statnews

Featured in: Favicon

statnews.com Favicon

businessinsider.com Favicon

foxnews.com Favicon

pbs.org

scientificamerican.com Favicon

flipboard.com Favicon

bostonglobe.com Favicon

wbur.org

theweek.com Favicon

medcitynews.com + 5 more

Articles

Insitro, Verastem treatment, chikungunya vaccine

1 week ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we talk about the FDA’s new artificial intelligence effort in the wake of mass layoffs, see AI darling Insitro cut staff, and more.
FDA will ask outside experts to review Capricor's therapy for Duchenne muscular dystrophy

1 week ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Today, we explore how an ambitious nonprofit is taking control of a shelved gene therapy, as it seeks to create a new model for commercializing treatments no longer deemed lucrative by pharma. Also, we see global scientific worry over internal NIH emails that say international collaborations may be cut off.
The impact of Trump's first 100 days on biotech

1 week ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today, we read about some candid conversations among biotech leaders at a Palo Alto conference, see the FDA rehire some laid-off workers, and more.
FDA approves blockbuster Dupixent for chronic hives

3 weeks ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we talk lots about tariffs — how they might impact drugmakers, patients, and even Ireland. Also, Novo Nordisk challenges Medicare over drug differentiation, and more. It seems it is only a matter of time before President Trump outlines new tariffs on the pharmaceuticals industry.
A very good day for Lilly, and a bad day for Novo

4 weeks ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning! Today we talk about Eli Lilly’s stock jumping after it released new data on its GLP-1 pill, see Sanofi partner with a mysterious company, and more. A very good day for Lilly, and a bad day for NovoFrom my colleague Elaine Chen: Eli Lilly’s stock shot up 14% yesterday, after the pharma giant reported the first Phase 3 results of its GLP-1 pill orforglipron.
Eli Lilly, NIH, FDA, Parkinson's cell therapy

4 weeks ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we talk about Arkansas making a bold move to curb PBM power, analyze Trump’s executive order in regards to drug prices, and more. A daily pill from Eli Lilly helped patients with type 2 diabetes improve their blood sugar and shed weight, the company said this morning, late-stage results that could propel the next-generation treatment onto the market.
Europe approves Leqembi for select Alzheimer's patients

1 month ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we discuss the latest executive order from President Trump, and also a surprisingly smooth meeting of CDC vaccine advisers. President Trump has issued a new executive order that takes aim at high drug prices and inefficiencies in Medicare. In a notable victory for the biotech and pharma industries, the order directs HHS Secretary Robert F.
J&J reports earnings beat as tariffs loom

1 month ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we see President Trump’s tariff plan for pharma start to take shape, note the biotech job vacuum growing in the Boston area, and see more scrutiny of PBMs. From my colleague Elaine Chen: Johnson & Johnson reported first-quarter sales and earnings that beat Wall Street expectations this morning.
Pfizer discontinues its experimental GLP-1 pill

1 month ago | statnews.com | Meghana Keshavan

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. Today, we discuss interesting new gene-editing data from Verve, see the NIH starting to convene advisory councils again, and more. Third Harmonic Bio, a company that has been developing treatments for inflammatory diseases, announced a plan to liquidate and dissolve itself.
NIH data ban blocks researchers in China, Russia, elsewhere

1 month ago | statnews.com | Meghana Keshavan

Hey there. Today, we talk about the NIH’s database ban on researchers in countries including China and Russia, discuss the legality of the HHS firings, and more. The XBI fell more than 4% yesterday. The closely tracked index of biotech stocks is now down 13% since the announcement of President Trump’s tariff policy. It’s down 22% for the year.